SPOTLIGHT: Merck touts reorganization efforts
Merck CEO Richard Clark (photo) has been using the company's annual business briefing to tout its reorganization efforts. More than half of the 7,000 announced job cuts have been made and Merck launched five new vaccines this year. Clark added that Merck has eight more products on the horizon, including three receiving regulatory scrutiny. NDAs for HIV, insomnia and heart disease are planned for 2007. Merck also faces 27,200 lawsuits over Vioxx. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
